News & Updates

Omeprazole helps inhibit fatty acid synthase activity in triple-negative breast cancer
Omeprazole helps inhibit fatty acid synthase activity in triple-negative breast cancer
08 Nov 2021

Fatty acid synthase (FASN) is commonly expressed in operable triple-negative breast cancer (TNBC) and is associated with a poor prognosis, but omeprazole can hamper FASN activity, which may potentially boost the efficacy of neoadjuvant chemotherapy, according to the results of a phase II study.

Omeprazole helps inhibit fatty acid synthase activity in triple-negative breast cancer
08 Nov 2021